How much does Revlimid cost with insurance?
For eligible patients with commercial or private insurance (including healthcare exchanges),* co-pay responsibility for REVLIMID is reduced to $25 (subject to annual benefit limit). For qualified patients who are uninsured or underinsured, REVLIMID may be available at no cost.
What are patient access schemes?
Patient access schemes are innovative pricing agreements proposed by pharmaceutical companies. They aim to improve cost-effectiveness and enable patients to gain access to high cost drugs and treatments. Companies may submit a patient access scheme proposal for any technology going through the NICE appraisal process.
What should I know before taking Revlimid Rems?
Before you begin taking REVLIMID, you must read and agree to all of the instructions in the REVLIMID REMS program. Before prescribing REVLIMID, your healthcare provider will explain the REVLIMID REMS program to you and have you sign the Patient-Physician Agreement Form. REVLIMID may cause serious side effects including:
Can I use other forms of birth control while on Revlimid?
Must agree to use two acceptable forms of birth control at the same time, for at least 4 weeks before, while taking, during any breaks (interruptions) in your treatment, and for at least 4 weeks after stopping REVLIMID.
How much is Revlimid a month?
Celgene launched Revlimid in 2005 at a price of $215 per pill. After more than 20 price hikes, the drug now costs $763 per pill, or $16,023 per month.
Is Revlimid considered a chemotherapy?
Revlimid | Chemotherapy Drug Information | Chemocare.com.
How long can you take Revlimid?
You won't take the drug on days 22 to 28. Revlimid can be taken for up to 12 cycles. Your doctor will likely prescribe Revlimid with the medication rituximab (Truxima, Rituxan).
What tier drug is Revlimid?
What drug tier is Revlimid typically on? Medicare prescription drug plans typically list Revlimid on Tier 5 of their formulary. Generally, the higher the tier, the more you have to pay for the medication.
What is the success rate of Revlimid?
Patients who took REVLIMID and dexamethasone continuously had a 75% response rate compared to 73% of patients who took REVLIMID and dexamethasone for only 18 months and 62% of patients who took the combination of melphalan, prednisone, and thalidomide.
How does Revlimid make you feel?
Treatment with REVLIMID can cause nausea. Nausea is an uneasy or unsettled feeling in the stomach. It often occurs at the same time with the urge to vomit, but doesn't always lead to vomiting. Some other ways people describe nausea are “feeling sick to my stomach,” “queasy,” or “upset stomach.”
How Long Can multiple myeloma stay in remission?
They indicate that a person may have a period of response to treatment that lasts 2 to 3 years or longer. Other research suggests the initial remission period may last 4 years or more.
What is the best time of day to take Revlimid?
REVLIMID is an oral medication taken once daily at about the same time each day, with or without food: You can take REVLIMID at home or wherever you choose. The recommended starting dose of REVLIMID is 25 mg/day for 21 days of a 28-day cycle; your doctor will tell you which dose is right for you.
Does Revlimid make you tired?
(Revlimid®) may cause fatigue at the start of treatment but can improve as the body learns to tolerate the drug. These treatments may also help relieve fatigue as the myeloma activity reduces.
When will Revlimid be generic?
Reddy's Laboratories, which settled with BMS in September to start a “volume-limited” launch of its own Revlimid generic during the same post-March 2022 timeframe. Like Sun, Dr. Reddy's deal tees up the company to sell the drug without restriction beginning in early 2026.
What can you not take with Revlimid?
Most frequently checked interactionsacyclovir.allopurinol.amlodipine.aspirin.atorvastatin.dexamethasone.furosemide.gabapentin.More items...
Can Revlimid cause eye problems?
Revlimid may cause eye problems. In studies, blurred vision and cataracts (cloudiness in the lens of the eye) were reported. Eye problems were less common than other side effects. Rarely, other eye problems have been reported in studies of Revlimid treatment for multiple myeloma.
Does Revlimid weaken your immune system?
Revlimid causes low white blood cells (neutropenia) and low platelets (thrombocytopenia) in most people. You may need a blood transfusion or certain medicines, if your blood counts drop too low.
What happens when you stop taking Revlimid?
No, stopping Revlimid treatment doesn't cause withdrawal symptoms. Withdrawal symptoms weren't reported as a side effect in people taking the medication in clinical studies. But if you stop taking Revlimid, your condition could worsen. You could also experience more symptoms of the condition.
What is the best maintenance drug for multiple myeloma?
Maintenance treatments containing the immunomodulatory therapy Revlimid (lenalidomide) are the best option for patients with multiple myeloma, according to a recent meta-analysis. The study, “Maintenance Treatment and Survival in Patients With Myeloma,” was published in the journal JAMA Oncology.
Does Revlimid make you tired?
(Revlimid®) may cause fatigue at the start of treatment but can improve as the body learns to tolerate the drug. These treatments may also help relieve fatigue as the myeloma activity reduces.
How to contact Celgene?
Email us at [email protected] or fax 1-800-822-2496.
Is Revlimid recommended for MCL?
REVLIMID ® is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials.
Who should report problems with a medicine?
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Is lenalidomide a third line treatment?
This guidance looks at the use of lenalidomide for multiple myeloma as third- or further-line treatment. For second-line use, please see NICE’s technology appraisal guidance on lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib.
Is this guidance up to date?
We reviewed the evidence in November 2012. We found nothing new that affects the recommendations in this guidance.
When was the voluntary scheme for branded medicines introduced?
Voluntary scheme for branded medicines pricing and access. The Voluntary Scheme for Branded Medicines Pricing and Access (VS) was introduced in January 2019. This will replace the 2014 Pharmaceutical Price Regulation Scheme (PPRS).
What is the complexity of NHS schemes?
The complexity of these schemes means that the review involves a high level of consultation with the NHS.
What is PASLU in healthcare?
The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment.
How long does it take to submit advice to NHSE&I?
We will usually submit our advice to NHSE&I within 4 weeks of the expert panel meeting, with a total review period of at least 12 weeks.
Is it possible to use expensive drugs in the NHS?
Drugs or treatments that are expensive and do not have a significant benefit over existing treatments are unlikely to be approved for use in the NHS.
Can companies submit a patient access scheme proposal?
Companies may submit a patient access scheme proposal for any technology going through the NICE appraisal process. We will look at the proposal to see if it is a scheme that would work in the NHS.
Contraindications
Warnings and Precautions
- Embryo-Fetal Toxicity: See Boxed WARNINGS. 1. Females of Reproductive Potential: See Boxed WARNINGS. 2. Males: Lenalidomide is present in the semen of patients receiving the drug. Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking REVLIMID and for up to 4 weeks after discontinuing REVLIMI…
Multiple Myeloma
- In newly diagnosed: The most frequently reported Grade 3 or 4 reactions included neutropenia, anemia, thrombocytopenia, pneumonia, asthenia, fatigue, back pain, hypokalemia, rash, cataract, lymphop...
- The most common adverse reactions reported in ≥20% (Arm Rd Continuous): diarrhea (45%), anemia (44%), neutropenia (35%), fatigue (33%), back pain (32%), asthenia (28%), insomnia (2…
- In newly diagnosed: The most frequently reported Grade 3 or 4 reactions included neutropenia, anemia, thrombocytopenia, pneumonia, asthenia, fatigue, back pain, hypokalemia, rash, cataract, lymphop...
- The most common adverse reactions reported in ≥20% (Arm Rd Continuous): diarrhea (45%), anemia (44%), neutropenia (35%), fatigue (33%), back pain (32%), asthenia (28%), insomnia (28%), rash (26%),...
- Maintenance Therapy Post Auto-HSCT:The most frequently reported Grade 3 or 4 reactions in ≥20% (REVLIMID arm) included neutropenia, thrombocytopenia, and leukopenia. The serious adverse reactions o...
- The most frequently reported adverse reactions in ≥20% (REVLIMID arm) across both mainte…
Drug Interactions
- Periodically monitor digoxin plasma levels due to increased Cmaxand AUC with concomitant REVLIMID therapy. Patients taking concomitant therapies such as ESAs or estrogen-containing therapies may have an increased risk of thrombosis. It is not known whether there is an interaction between dexamethasone and warfarin. Close monitoring of PT and INR is recommen…
Use in Specific Populations
- PREGNANCY: See Boxed WARNINGS:If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for f...
- LACTATION: There is no information regarding the presence of lenalidomide in human milk, the effects of REVLIMID on the breastfed infant, or the effects of REVLIMID on milk productio…
- PREGNANCY: See Boxed WARNINGS:If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for f...
- LACTATION: There is no information regarding the presence of lenalidomide in human milk, the effects of REVLIMID on the breastfed infant, or the effects of REVLIMID on milk production. Because many...
- RENAL IMPAIRMENT: Adjust the starting dose of REVLIMID based on creatinine clearance value and for patients on dialysis.
Contraindications
- Pregnancy:REVLIMID can cause fetal harm when administered to a pregnant female and is contraindicated in females who are pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to the fetus. Severe Hypersensitivity Reactions:REVLIMID is contraind...
Warnings and Precautions
- Embryo-Fetal Toxicity: See Boxed WARNINGS. 1. Females of Reproductive Potential: See Boxed WARNINGS. 2. Males: Lenalidomide is present in the semen of patients receiving the drug. Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking REVLIMID and for up to 4 weeks after discontinuing REVLIMI…
Adverse Reactions
- Mantle Cell Lymphoma 1. Grade 3 and 4 adverse events reported in ≥5% of patients treated with REVLIMID in the MCL trial (N=134) included neutropenia (43%), thrombocytopenia (28%), anemia (11%), pneumonia (9%), leukopenia (7%), fatigue (7%), diarrhea (6%), dyspnea (6%), and febrile neutropenia (6%). 2. Adverse events reported in ≥15% of patients treated with REVLIMID in the M…
Drug Interactions
- Periodically monitor digoxin plasma levels due to increased Cmaxand AUC with concomitant REVLIMID therapy. Patients taking concomitant therapies such as ESAs or estrogen-containing therapies may have an increased risk of thrombosis. It is not known whether there is an interaction between dexamethasone and warfarin. Close monitoring of PT and INR is recommen…
Use in Specific Populations
- PREGNANCY: See Boxed WARNINGS:If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for f...
- LACTATION: There is no information regarding the presence of lenalidomide in human milk, the effects of REVLIMID on the breastfed infant, or the effects of REVLIMID on milk productio…
- PREGNANCY: See Boxed WARNINGS:If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for f...
- LACTATION: There is no information regarding the presence of lenalidomide in human milk, the effects of REVLIMID on the breastfed infant, or the effects of REVLIMID on milk production. Because many...
- RENAL IMPAIRMENT: Adjust the starting dose of REVLIMID based on creatinine clearance value and for patients on dialysis.